Can Molecular Biomarkers be Utilized to Determine Appropriate Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC)?

Kumar, Prashanth Ashok; Basnet, Alina; Graziano, Stephen

Kumar, Prashanth Ashok; Basnet, Alina; Graziano, Stephen.

Afiliação

Kumar PA; Division of Hematology-Medical Oncology, Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA.
Basnet A; Division of Hematology-Medical Oncology, Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA.
Graziano S; Division of Hematology-Medical Oncology, Upstate Cancer Center, SUNY Upstate Medical University, Syracuse, NY, USA.

J Cell Immunol ; 6(2): 82-86, 2024.

Article em En | MEDLINE | ID: mdl-38957649

Palavras-chave

Adjuvant chemotherapy; Early-stage NSCLC; Immunotherapy; LACE Bio

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Cell Immunol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google